
    
      This study consisted of the following phases: screening, 4-week baseline phase, 12-week
      double-blind treatment, and 12-week follow-up. Participants may have elected to participate
      in the optional pharmacokinetic substudy and the optional, novel patient-reported outcome
      (PRO) assessment substudy.

      Participants who completed the 12-week double-blind treatment phase of Study 20120295 were
      eligible to enroll in an open-label extension study (Study 20130255; NCT02174861).
    
  